Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval of the MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer in the United States. The approval is based on final PRIMA trial data and establishes MyChoice CDx as the only FDA-authorized CDx for Zejula.
The test uses next-generation sequencing to assess BRCA1/2 (including large rearrangements) and a tumor genomic instability score (LOH, TAI, LST) to determine HRD status for treatment decisions.
Myriad (NASDAQ: MYGN) launched the Precise MRD tumor-informed circulating tumor DNA (ctDNA) test on March 2, 2026, with a select group of community oncologists for patients with breast cancer.
The assay uses whole-genome sequencing to create personalized tests and enables ultrasensitive ctDNA detection down to one part per million. Myriad plans a broader U.S. commercial rollout later in 2026, with no limit on participating patients in the initial release.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.
Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.
Myriad Genetics (NASDAQ: MYGN) reported Q4 2025 revenue of $209.8 million and full‑year 2025 revenue of $824.5 million (down 2% YoY). Test volume was 382,000 in Q4, up 2% YoY. Q4 GAAP net loss was $7.9 million; adjusted EBITDA was $14.3 million. The company reiterated 2026 guidance of $860–$880 million revenue and 68–69% adjusted gross margin, with adjusted EBITDA guidance of $37–$49 million.
Management highlighted Prolaris, GeneSight, and three planned 2026 test launches (Precise MRD, AI-enabled Prolaris, FirstGene) as drivers for growth.
Myriad Genetics (NASDAQ: MYGN) announced publication of the analytical validation of the FirstGene Multiple Prenatal Screen in Clinical Chemistry on February 19, 2026. Using nearly 500 samples, the study reported each test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity.
The assay evaluates fetal aneuploidy, RhD compatibility, and recessive condition status for the pregnant person and fetus across 19 prevalent severe conditions. The test uses fetal-fraction amplification and a trajectory analysis algorithm to improve genotype resolution and reproducibility, which the company says supports broader commercialization efforts.
Myriad Genetics (NASDAQ: MYGN) will release its fourth quarter and full year 2025 financial results and hold an earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The earnings release will be issued after market close the same day.
Management will provide a financial overview and business update; a live webcast and archived replay will be available at the company's Investor Relations website. Company executives will also appear at three investor healthcare conferences in March 2026.
Myriad Genetics (NASDAQ: MYGN) plans a limited clinical launch of Precise MRD in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later in 2026, with potential further expansion in 2027.
Key study data show ultrasensitive ctDNA detection down to 1 part-per-million, 93% baseline sensitivity in MONITOR-Breast, and 100% baseline detection plus 100% one-month post-surgery sensitivity for recurrence prediction in MONSTAR-SCREEN-3; one-month postoperative ctDNA positivity was linked to shorter disease-free survival (median follow-up ~6 months, p<0.001).
Myriad Genetics (NASDAQ: MYGN) released select unaudited preliminary results for Q4 and full year 2025 and introduced full‑year 2026 guidance on Jan 12, 2026.
Preliminary revenue: Q4 2025 $207M–$209M; full year 2025 $822M–$824M. 2026 guidance: Revenue $860M–$880M, Adjusted Gross Margin 68%–69%, and Adjusted EBITDA $37M–$49M. The company will publish final audited results in February 2026 and host a webcast on Jan 14, 2026 at 5:15 pm PT.
Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.